Publish Date: June 2015
Author: Andrés Pichon-Riviere, Demián Glujovsky, Osvaldo Ulises Garay, Federico Augustovski, Agustin Ciapponi, Magdalena Serpa and Fernando Althabe
Despite strong evidence showing the efficacy of routine oxytocin in preventing postpartum hemorrhage, the proportion of women receiving it after delivery is still below 100%. The Uniject injection system prefilled with oxytocin (Uniject) has the potential advantage, due to its ease of use, to increase oxytocin utilization rates.
The authors aimed to assess its cost-effectiveness in Latin America and the Caribbean. We used an epidemiological model to estimate:
a) The impact of replacing oxytocin in ampoules with Uniject on the incidence of PPH, quality-adjusted life years (QALYs) and costs from a health care system perspective; and
b) The minimum increment in oxytocin utilization rates required to make Uniject a cost-effective strategy.
The open access article is available on the PLOS One website.